drugset / Trial / NCT06660693

Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis

NCT06660693

Phase 3 Recruiting 134 enrolled McMaster University AbbVie · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by infliximab in upadacitinib non-responders is non-inferior to conventional management with infliximab only.

Timeline

Start
2025-04-16
Primary completion
2027-05
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Upadacitinib Small molecule 45 mg Oral

Indications